1. Home
  2. EVAX vs AYTU Comparison

EVAX vs AYTU Comparison

Compare EVAX & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EVAX

Evaxion Biotech

N/A

Current Price

$3.30

Market Cap

27.4M

Sector

Health Care

ML Signal

N/A

Logo Aytu BioPharma Inc.

AYTU

Aytu BioPharma Inc.

N/A

Current Price

$2.67

Market Cap

25.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EVAX
AYTU
Founded
2008
N/A
Country
Denmark
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.4M
25.7M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
EVAX
AYTU
Price
$3.30
$2.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$12.33
$9.33
AVG Volume (30 Days)
23.4K
42.5K
Earning Date
01-01-0001
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$27,632,080.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$44.11
P/E Ratio
N/A
N/A
Revenue Growth
N/A
277.47
52 Week Low
$1.20
$0.95
52 Week High
$12.15
$3.07

Technical Indicators

Market Signals
Indicator
EVAX
AYTU
Relative Strength Index (RSI) 53.08 58.43
Support Level $2.92 $2.14
Resistance Level $5.48 $2.66
Average True Range (ATR) 0.25 0.13
MACD 0.07 0.03
Stochastic Oscillator 100.00 83.02

Price Performance

Historical Comparison
EVAX
AYTU

About EVAX Evaxion Biotech

Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

Share on Social Networks: